DK39892D0 - Peptid - Google Patents
PeptidInfo
- Publication number
- DK39892D0 DK39892D0 DK92398A DK39892A DK39892D0 DK 39892 D0 DK39892 D0 DK 39892D0 DK 92398 A DK92398 A DK 92398A DK 39892 A DK39892 A DK 39892A DK 39892 D0 DK39892 D0 DK 39892D0
- Authority
- DK
- Denmark
- Prior art keywords
- glp
- pct
- agonists
- receptor
- sec
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 abstract 2
- 102100040918 Pro-glucagon Human genes 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 238000012216 screening Methods 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/605—Glucagons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK92398A DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Peptid |
| PCT/EP1993/000697 WO1993019175A1 (en) | 1992-03-25 | 1993-03-23 | Receptor for the glucagon-like-peptide-1 (glp-1) |
| AT93906589T ATE184648T1 (de) | 1992-03-25 | 1993-03-23 | Receptor für das glucagon ähnliches peptid-1 (glp-1) |
| EP93906589A EP0586657B1 (en) | 1992-03-25 | 1993-03-23 | Receptor for the glucagon-like-peptide-1 (glp-1) |
| DE0586657T DE586657T1 (de) | 1992-03-25 | 1993-03-23 | Receptor für das Glucagon ähnliches Peptid-1 (GLP-1). |
| US08/142,439 US5670360A (en) | 1992-03-25 | 1993-03-23 | Mammalian receptors for glucagon-like-peptide-1 (GLP-1), corresponding DNA and recombinant expression systems, and screening assays for GLP-1 agonists and enhancers |
| JP51628793A JP3371379B2 (ja) | 1992-03-25 | 1993-03-23 | グルカゴン様ペプチド−１（ｇｌｐ−１）に対するレセプター |
| ES93906589T ES2070801T1 (es) | 1992-03-25 | 1993-03-23 | Receptor para el peptido-1 similar al glucagon (glp-1). |
| DE69326405T DE69326405T2 (de) | 1992-03-25 | 1993-03-23 | Receptor für das Glucagon ähnliches Peptid-1 (GLP-1) |
| AU37512/93A AU3751293A (en) | 1992-03-25 | 1993-03-23 | Receptor for the glucagon-like-peptide-1 (GLP-1) |
| GR950300031T GR950300031T1 (en) | 1992-03-25 | 1995-06-30 | Receptor for the glucagon-like-peptide-1 (glp-1). |
| US08/869,477 US5846747A (en) | 1992-03-25 | 1997-06-05 | Method for detecting glucagon-like peptide-1 antagonists and agonists |
| US08/935,317 US6051689A (en) | 1992-03-25 | 1997-09-22 | Receptor for the glucagon-like-peptide (GLP-1) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK92398A DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Peptid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK39892D0 true DK39892D0 (da) | 1992-03-25 |
Family
ID=8093079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK92398A DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Peptid |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US5670360A (da) |
| EP (1) | EP0586657B1 (da) |
| JP (1) | JP3371379B2 (da) |
| AT (1) | ATE184648T1 (da) |
| AU (1) | AU3751293A (da) |
| DE (2) | DE69326405T2 (da) |
| DK (1) | DK39892D0 (da) |
| ES (1) | ES2070801T1 (da) |
| GR (1) | GR950300031T1 (da) |
| WO (1) | WO1993019175A1 (da) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6849708B1 (en) | 1986-05-05 | 2005-02-01 | The General Hospital Corporation | Insulinotropic hormone and uses thereof |
| US7138486B2 (en) | 1986-05-05 | 2006-11-21 | The General Hospital Corporation | Insulinotropic hormone derivatives and uses thereof |
| US5614492A (en) * | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| US5846747A (en) * | 1992-03-25 | 1998-12-08 | Novo Nordisk A/S | Method for detecting glucagon-like peptide-1 antagonists and agonists |
| DK39892D0 (da) * | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
| BR9306551A (pt) * | 1992-06-15 | 1998-09-15 | Pfizer | Derivados de peptídeo do tipo glucagona e de insulinotropina |
| ATE285472T1 (de) * | 1992-08-28 | 2005-01-15 | Novo Nordisk As | Glucagonrezeptoren |
| US6284727B1 (en) | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
| EP0716694A4 (en) * | 1993-08-09 | 1997-06-04 | Merck & Co Inc | HUMAN GLUCAGON-LIKE 1 PEPTID RECEPTOR |
| GB9502830D0 (en) * | 1995-02-14 | 1995-04-05 | Ecole Polytech | Regulation of polypeptide production in cells |
| US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| WO1998025955A2 (en) * | 1996-12-13 | 1998-06-18 | Allelix Biopharmaceuticals Inc. | Cloned glucagon-like peptide-2 receptors |
| US8592553B2 (en) | 1996-12-13 | 2013-11-26 | Nps Pharmaceuticals, Inc. | Cloned glucagon-like peptide-2 receptors |
| EP1100530B1 (en) | 1998-07-31 | 2003-10-08 | Novo Nordisk A/S | In-vitro stimulation of beta cell proliferation |
| WO2000025134A1 (en) * | 1998-10-23 | 2000-05-04 | Glaxo Group Limited | Assays for ligands for nuclear receptors |
| WO2001066135A1 (en) | 2000-03-08 | 2001-09-13 | Novo Nordisk A/S | Lowering serum lipids |
| US6448045B1 (en) * | 2000-03-10 | 2002-09-10 | The Regents Of The University Of California | Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1 |
| US20020123071A1 (en) * | 2000-12-04 | 2002-09-05 | Knudsen Sanne Moller | Method of identifying compounds capable of acting as agonists or antagonists of G-protein coupled receptors |
| US6642003B2 (en) | 2001-08-02 | 2003-11-04 | Cedars-Sinai Medical Center | Human glucose-dependent insulin-secreting cell line |
| BR0212985A (pt) | 2001-09-24 | 2005-08-30 | Imp College Innovations Ltd | Uso de pyy ou de um agonista do mesmo na preparação de medicamentos para tratamento de distúrbios associados com excesso de peso |
| US6911324B2 (en) | 2001-10-18 | 2005-06-28 | The Regents Of The University Of California | Induction of beta cell differentiation in human cells |
| CA2472882A1 (en) | 2002-01-10 | 2003-07-17 | Imperial College Innovations Ltd | Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour |
| US7141240B2 (en) * | 2002-03-12 | 2006-11-28 | Cedars-Sinai Medical Center | Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1 |
| MXPA04012497A (es) | 2002-07-04 | 2005-07-14 | Zealand Pharma As | Glp-1 y metodos para tratar la diabetes. |
| PL377591A1 (pl) * | 2002-10-02 | 2006-02-06 | Zealand Pharma A/S | Stabilizowane związki eksendyny-4 |
| US7790681B2 (en) * | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
| US20040209803A1 (en) * | 2002-12-19 | 2004-10-21 | Alain Baron | Compositions for the treatment and prevention of nephropathy |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| WO2004071393A2 (en) * | 2003-02-13 | 2004-08-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with glucagon-like peptide 1 receptor (glp1r) |
| WO2005018536A2 (en) * | 2003-05-23 | 2005-03-03 | Human Genome Sciences, Inc. | Agonist antibodies that specifically bind the glucagon like peptide-1 receptor |
| DK3300721T4 (da) | 2003-11-20 | 2025-03-03 | Novo Nordisk As | Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger |
| EP1694356B1 (en) | 2003-12-09 | 2011-02-16 | Novo Nordisk A/S | Regulation of food preference using glp-1 agonists |
| JP2008501765A (ja) | 2004-06-11 | 2008-01-24 | ノボ ノルディスク アクティーゼルスカブ | Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和 |
| EP1896605A4 (en) | 2005-06-07 | 2010-09-01 | Univ Rockefeller | Stimulation of proliferation of pancreatic B cells |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| WO2009126709A1 (en) * | 2008-04-09 | 2009-10-15 | Transtech Pharma, Inc. | Ligands for the glp-1 receptor and methods for discovery thereof |
| EP3228320B1 (de) | 2008-10-17 | 2019-12-18 | Sanofi-Aventis Deutschland GmbH | Kombination von einem insulin und einem glp-1-agonisten |
| EP3202394A1 (de) | 2009-07-06 | 2017-08-09 | Sanofi-Aventis Deutschland GmbH | Wässrige insulinzubereitungen enthaltend methionin |
| PT2554183T (pt) | 2009-11-13 | 2018-07-09 | Sanofi Aventis Deutschland | Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina |
| PE20121316A1 (es) | 2009-11-13 | 2012-10-05 | Sanofi Aventis Deutschland | Composicion farmaceutica que comprende un agonista de glp-1 y metionina |
| WO2011123943A1 (en) | 2010-04-09 | 2011-10-13 | Mount Sinai Hospital | Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist |
| SG184988A1 (en) | 2010-04-27 | 2012-11-29 | Zealand Pharma As | Peptide conjugates of glp-1 receptor agonists and gastrin and their use |
| US20140148384A1 (en) | 2010-08-30 | 2014-05-29 | Sanofi-Aventis Deutschland Gmbh | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
| MX345501B (es) | 2010-12-16 | 2017-02-02 | Novo Nordisk As | Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico. |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| CN108079281A (zh) | 2011-08-29 | 2018-05-29 | 赛诺菲-安万特德国有限公司 | 用于2型糖尿病患者中的血糖控制的药物组合 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| CA2853884A1 (en) | 2011-11-03 | 2013-05-10 | Zealand Pharma A/S | Glp-1 receptor agonist peptide gastrin conjugates |
| EP2788027A2 (en) | 2011-12-09 | 2014-10-15 | Novo Nordisk A/S | Glp-1 agonists |
| WO2013139695A1 (en) | 2012-03-22 | 2013-09-26 | Novo Nordisk A/S | Compositions comprising a delivery agent and preparation thereof |
| EP2827885B1 (en) | 2012-03-22 | 2018-08-15 | Novo Nordisk A/S | Compositions of glp-1 peptides and preparation thereof |
| HRP20251088T1 (hr) | 2012-07-01 | 2025-11-07 | Novo Nordisk A/S | Upotreba dugodjelujućih peptida glp‑1 |
| MY170671A (en) | 2012-07-23 | 2019-08-26 | Zealand Pharma As | Glucagon analogues |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| US20150273069A1 (en) | 2012-10-17 | 2015-10-01 | Novo Nordisk A/S | Fatty acid acylated amino acids for oral peptide delivery |
| TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| SI3057984T1 (sl) | 2013-10-17 | 2018-10-30 | Zealand Pharma A/S | Acilirani glukagonski analogi |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| US10093713B2 (en) | 2013-11-06 | 2018-10-09 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
| EA035688B1 (ru) | 2013-11-06 | 2020-07-27 | Зилэнд Фарма А/С | Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip |
| CN105899191B (zh) | 2014-01-09 | 2020-06-16 | 赛诺菲 | 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂 |
| KR20160104724A (ko) | 2014-01-09 | 2016-09-05 | 사노피 | 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 약제학적 제형 |
| RU2016132340A (ru) | 2014-01-09 | 2018-02-14 | Санофи | Стабилизированные фармацевтические составы на основе инсулина аспарта |
| EP3006045B3 (en) | 2014-10-07 | 2021-03-17 | Cyprumed GmbH | Pharmaceutical formulations for the oral delivery of peptide or protein drugs |
| TWI705973B (zh) | 2014-10-29 | 2020-10-01 | 丹麥商西蘭製藥公司 | Ｇｉｐ促效劑化合物及方法 |
| TWI758239B (zh) | 2014-12-12 | 2022-03-21 | 德商賽諾菲阿凡提斯德意志有限公司 | 甘精胰島素/利司那肽固定比率配製劑 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| TWI707867B (zh) | 2015-04-16 | 2020-10-21 | 丹麥商西蘭製藥公司 | 醯化之昇糖素類似物 |
| CA2997343A1 (en) | 2015-10-07 | 2017-04-13 | Cyprumed Gmbh | Pharmaceutical formulations for the oral delivery of peptide drugs |
| WO2018065634A1 (en) | 2016-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical compositions for the nasal delivery of peptide or protein drugs |
| WO2018104561A1 (en) | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
| TWI847306B (zh) | 2017-08-24 | 2024-07-01 | 丹麥商諾佛 儂迪克股份有限公司 | Ｇｌｐ-１組成物及其用途 |
| EP4299118A3 (en) | 2018-02-02 | 2024-04-10 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
| EP3773475A1 (en) | 2018-04-06 | 2021-02-17 | Cyprumed GmbH | Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| CN111423506B (zh) * | 2019-11-08 | 2023-06-27 | 成都奥达生物科技有限公司 | 一种glp-1化合物 |
| BR112022013795A2 (pt) | 2020-02-18 | 2022-09-13 | Novo Nordisk As | Composição farmacêutica líquida, e, kit |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| US20230165939A1 (en) | 2020-04-29 | 2023-06-01 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and histidine |
| WO2022049310A1 (en) | 2020-09-07 | 2022-03-10 | Cyprumed Gmbh | Improved pharmaceutical formulations of glp-1 receptor agonists |
| WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
| AU2023415591A1 (en) | 2022-12-30 | 2025-08-14 | Algipharma As | Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (en) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK39892D0 (da) * | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
-
1992
- 1992-03-25 DK DK92398A patent/DK39892D0/da not_active Application Discontinuation
-
1993
- 1993-03-23 ES ES93906589T patent/ES2070801T1/es active Pending
- 1993-03-23 WO PCT/EP1993/000697 patent/WO1993019175A1/en not_active Ceased
- 1993-03-23 DE DE69326405T patent/DE69326405T2/de not_active Expired - Lifetime
- 1993-03-23 DE DE0586657T patent/DE586657T1/de active Pending
- 1993-03-23 JP JP51628793A patent/JP3371379B2/ja not_active Expired - Lifetime
- 1993-03-23 AT AT93906589T patent/ATE184648T1/de not_active IP Right Cessation
- 1993-03-23 US US08/142,439 patent/US5670360A/en not_active Expired - Lifetime
- 1993-03-23 AU AU37512/93A patent/AU3751293A/en not_active Abandoned
- 1993-03-23 EP EP93906589A patent/EP0586657B1/en not_active Expired - Lifetime
-
1995
- 1995-06-30 GR GR950300031T patent/GR950300031T1/el unknown
-
1997
- 1997-09-22 US US08/935,317 patent/US6051689A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ATE184648T1 (de) | 1999-10-15 |
| DE69326405T2 (de) | 2000-03-23 |
| WO1993019175A1 (en) | 1993-09-30 |
| US6051689A (en) | 2000-04-18 |
| EP0586657A1 (en) | 1994-03-16 |
| JP3371379B2 (ja) | 2003-01-27 |
| DE69326405D1 (de) | 1999-10-21 |
| DE586657T1 (de) | 1996-01-18 |
| US5670360A (en) | 1997-09-23 |
| JPH06508765A (ja) | 1994-10-06 |
| ES2070801T1 (es) | 1995-06-16 |
| EP0586657B1 (en) | 1999-09-15 |
| AU3751293A (en) | 1993-10-21 |
| GR950300031T1 (en) | 1995-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK39892D0 (da) | Peptid | |
| DK1482042T3 (da) | Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren | |
| DK0758383T3 (da) | Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof | |
| ATE193541T1 (de) | Insulinotropes hormon | |
| HRP20020996B1 (hr) | Analozi peptida-1 nalik na glukagon | |
| IL112112A (en) | Peptides with growth hormone releasing properties and pharmaceutical compositions containing them | |
| DK0667910T3 (da) | En Bacillus-promoter, afledt fra en variant af en alpha-amylase-promoter fra Bacillus licheniformis | |
| DK0675956T3 (da) | Nyt protein fra urin betegnet komponent B | |
| DE69938669D1 (de) | Analoge des glucagon ähnlichen peptides-1 (glp-1) | |
| DK0591914T3 (da) | Retrovirus fra HIV-gruppen og dets anvendelse | |
| DK0479948T3 (da) | Sammensætninger og fremgangsmåder til syntese af natriuretisk protein-receptor B og anvendelsesfremgangsmåder | |
| ATE184022T1 (de) | Neuropeptide y antagoniste | |
| AU1208497A (en) | Ligand polypeptides for the g-protein-coupled receptor protein, their production and use | |
| ATE389416T1 (de) | Behandlung von knorpelerkrankungen | |
| DK0395853T3 (da) | Rekombinant proteinreceptor | |
| NO951689D0 (no) | DNA som koder for en human serotoninreseptor (5-HT4B) og anvendelse av denne | |
| ATE225806T1 (de) | D-2-alkyltryptophan enthaltende polypeptide mit wachstumhormon freisetzender aktivitaet | |
| DE59206628D1 (en) | Expression signalpeptid-freier staphylokinasen | |
| DK0773999T3 (da) | OR-1, en orphan-receptor tilhørende kernereceptorfamilien | |
| ATE254179T1 (de) | Neue type-i-interferon varianten, ihre verfahren zur herstellung, und ihre verwendungen | |
| ATE358682T1 (de) | Klonierte rezeptoren des glukagon-ähnlichen peptids-2 | |
| FR2693200B1 (fr) | Nouveaux polypeptides ayant une activité de récepteur sérotoninergique, acides nucléiques codant pour ces polypeptides et utilisations. | |
| ES2059801T3 (es) | Nuevas linfoquinas, secuencias de adn que codifican para estas linfoquinas, y composiciones farmaceuticas conteniendo estas linfoquinas. | |
| DK0487229T3 (da) | DNA, der koder for et protein, som binder til enhanceren for alfa-føtoproteingenet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AHS | Application shelved for other reasons than non-payment |